{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:50:00Z","timestamp":1772722200703,"version":"3.50.1"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["CNE - E-26\/200.798\/2021"],"award-info":[{"award-number":["CNE - E-26\/200.798\/2021"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["Apoio \u00e0s Institui\u00e7\u00f5es de Ensino Sediadas no RJ"],"award-info":[{"award-number":["Apoio \u00e0s Institui\u00e7\u00f5es de Ensino Sediadas no RJ"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["Faixa C"],"award-info":[{"award-number":["Faixa C"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/010.000175\/2016"],"award-info":[{"award-number":["E-26\/010.000175\/2016"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["PQ2\/305872\/2016-8"],"award-info":[{"award-number":["PQ2\/305872\/2016-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["CAPES\/Ci\u00eancias sem Fronteiras\/Pesquisador Visitante Especial\/88881.062218\/2014-0"],"award-info":[{"award-number":["CAPES\/Ci\u00eancias sem Fronteiras\/Pesquisador Visitante Especial\/88881.062218\/2014-0"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Brain Tumor Pathol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10014-022-00441-6","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T18:02:41Z","timestamp":1655748161000},"page":"183-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Aggressive nonfunctioning pituitary neuroendocrine tumors"],"prefix":"10.1007","volume":"39","author":[{"given":"S\u00e9rgio","family":"Portovedo","sequence":"first","affiliation":[]},{"given":"Leonardo Vieira","family":"Neto","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Soares","sequence":"additional","affiliation":[]},{"given":"Denise Pires de","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Christina Maeda","family":"Takiya","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7832-8717","authenticated-orcid":false,"given":"Leandro","family":"Miranda-Alves","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"441_CR1","unstructured":"Osamura RY, Grossman A, Korbonits M, Kovacs K, Lopes MBS, Matsuno A, et al (2017) Tumors of the pituitary gland. In: Lloyd RV, Osamura RY, Kl\u00f6ppel G, Rosai J (eds). WHO Classification of Tumours of Endocrine Organs; 4th ed. WHO International Agency for Research and Cancer (IARC), Lyon, pp 14\u201318"},{"key":"441_CR2","doi-asserted-by":"publisher","first-page":"C5","DOI":"10.1530\/ERC-17-0004","volume":"24","author":"SL Asa","year":"2017","unstructured":"Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N et al (2017) From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 24:C5\u2013C8","journal-title":"Endocr Relat Cancer"},{"key":"441_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00428-019-02655-0","volume":"475","author":"C Villa","year":"2019","unstructured":"Villa C, Vasiljevic A, Jaffrain-Rea ML, Ansorge O, Asioli S, Barresi V, Chinezu L, Gardiman MP, Lania A, Lapshina AM, Poliani L et al (2019) A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch 475:687\u2013692","journal-title":"Virchows Arch"},{"key":"441_CR4","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","volume":"31","author":"G Rindi","year":"2018","unstructured":"Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, Krijger RR, Dietel M, El-Naggar AK et al (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) Expert Consensus proposal. Mod Pathol 31:1770\u20131786","journal-title":"Mod Pathol"},{"key":"441_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s11102-019-00988-2","volume":"22","author":"KKY Ho","year":"2019","unstructured":"Ho KKY, Fleseriu M, Wass J, van der Lely A, Barkan A, Giustina A, Casanueva FF, Heaney AP, Biermasz N, Strasburger C et al (2019) A tale of pituitary adenomas: to NET or not to NET. Pituitary 22:569\u2013573","journal-title":"Pituitary"},{"key":"441_CR6","unstructured":"Klimstra DS, Kl\u00f6ppel G, La Rosa S, Rindi G (2019) Classification of neuroendocrine neoplasms of the digestive system. In: Arends MJ, Fukuyama M, Klimstra DS, Lam, AKY, Nagtegaal ID, Odze RD. WHO Classification of Tumours: Digestive system Tumors, 5th ed. WHO International Agency for Research and Cancer (IARC), Lyon, pp.17\u201322."},{"key":"441_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12022-021-09678-x","volume":"32","author":"SL Asa","year":"2021","unstructured":"Asa SL (2021) Challenges in the diagnosis of pituitary neuroendocrine tumors. Endocr Pathol 32:222\u2013227","journal-title":"Endocr Pathol"},{"key":"441_CR8","volume-title":"World Health Organization classification of tumours of endocrine organs","author":"RV Lloyd","year":"2017","unstructured":"Lloyd RV, Osamura RY, Kl\u00f6ppel G et al (2017) World Health Organization classification of tumours of endocrine organs, 4th edn. IARC Publication, Lyon","edition":"4"},{"key":"441_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000339823","volume":"96","author":"Y Chen","year":"2012","unstructured":"Chen Y, Wang CD, Su ZP, Chen YX, Cai L, Zhuge QC, Wu ZB (2012) Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96:333\u2013342","journal-title":"Neuroendocrinology"},{"key":"441_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1530\/eje.1.02298","volume":"155","author":"E Ferrante","year":"2006","unstructured":"Ferrante E, Ferraroni M, Castrignan\u00f2 T, Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli P, Faustini-Fustini M et al (2006) Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 155:823\u2013829","journal-title":"Eur J Endocrinol"},{"key":"441_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/modpathol.2015.151","volume":"29","author":"O Mete","year":"2016","unstructured":"Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S, Asa SL (2016) Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol 29:131\u2013142","journal-title":"Mod Pathol"},{"key":"441_CR12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/j.1365-2265.2007.02990.x","volume":"67","author":"N Karavitaki","year":"2007","unstructured":"Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S, Wass JA (2007) What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol 67:938\u2013943","journal-title":"Clin Endocrinol"},{"key":"441_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11102-018-0869-3","volume":"21","author":"G Ntali","year":"2018","unstructured":"Ntali G, Wass JA (2018) Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary 21:111\u2013118","journal-title":"Pituitary"},{"key":"441_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s42000-019-00168-8","volume":"19","author":"M Araujo-Castro","year":"2020","unstructured":"Araujo-Castro M, Berrocal VR, Pascual-Corrales E (2020) Pituitary tumors: epidemiology and clinical presentation spectrum. Hormones (Athens) 19:145\u2013155","journal-title":"Hormones (Athens)"},{"key":"441_CR15","first-page":"2000","volume-title":"Endotext","author":"JB Drummond","year":"2018","unstructured":"Drummond JB, Ribeiro-Oliveira A Jr, Soares BS, Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K et al (2018) Non-functioning pituitary adenomas. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferr\u00e8re B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP (eds) Endotext. MDText.com Inc, South Dartmouth, p 2000"},{"key":"441_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1586\/17446651.2016.1153422","volume":"11","author":"SL Asa","year":"2016","unstructured":"Asa SL, Ezzat S (2016) Aggressive pituitary tumors or localized pituitary carcinomas: defining pituitary tumors. Expert Rev Endocrinol Metab 11:149\u2013162","journal-title":"Expert Rev Endocrinol Metab"},{"key":"441_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00701-017-3396-5","volume":"160","author":"F Ceccato","year":"2018","unstructured":"Ceccato F, Regazzo D, Barbot M, Denaro L, Emanuelli E, Borsetto D, Rolma G, Alessio L, Gardiman MP, Lombardi G et al (2018) Early recognition of aggressive pituitary adenomas: a single-centre experience. Acta Neurochir 160:49\u201355","journal-title":"Acta Neurochir"},{"key":"441_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000371806","volume":"101","author":"E Chatzellis","year":"2015","unstructured":"Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G (2015) Aggressive pituitary tumors. Neuroendocrinology 101:87\u2013104","journal-title":"Neuroendocrinology"},{"key":"441_CR19","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1517\/14656566.2011.568478","volume":"12","author":"A Colao","year":"2011","unstructured":"Colao A, Grasso LFS, Pivonello R, Lombardi G (2011) Therapy of aggressive pituitary tumors. Expert Opin Pharmacother 12:1561\u20131570","journal-title":"Expert Opin Pharmacother"},{"key":"441_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrendo.2014.64","volume":"10","author":"A Di Ieva","year":"2014","unstructured":"Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K (2014) Aggressive pituitary adenomas\u2014diagnosis and emerging treatments. Nat Rev Endocrinol 10:423\u2013435","journal-title":"Nat Rev Endocrinol"},{"key":"441_CR21","doi-asserted-by":"publisher","first-page":"R559","DOI":"10.1530\/ERC-18-0228","volume":"25","author":"D Dworakowska","year":"2018","unstructured":"Dworakowska D, Grossman AB (2018) Aggressive and malignant pituitary tumours: state-of-the-art. Endocr-Relat Cancer 25:R559\u2013R575","journal-title":"Endocr-Relat Cancer"},{"key":"441_CR22","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1530\/JME-12-0113","volume":"49","author":"O Mete","year":"2012","unstructured":"Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49:R69\u2013R78","journal-title":"J Mol Endocrinol"},{"key":"441_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.wneu.2016.09.092","volume":"97","author":"SM Priola","year":"2017","unstructured":"Priola SM, Esposito F, Cannav\u00f2 S, Conti A, Abbritti RV, Barresi V, Baldari S, Ferra\u00f9 F, German\u00f2 A, Tomasello F et al (2017) Aggressive pituitary adenomas: the dark side of the moon. World Neurosurg 97:140\u2013155","journal-title":"World Neurosurg"},{"key":"441_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ecl.2014.10.008","volume":"44","author":"A Sav","year":"2015","unstructured":"Sav A, Rotondo F, Syro LV, Di Ieva A, Cusimano MD, Kovacs K (2015) Invasive, atypical and aggressive pituitary adenomas and carcinomas. Endocrinol Metab Clin N Am 44:99\u2013104","journal-title":"Endocrinol Metab Clin N Am"},{"key":"441_CR25","doi-asserted-by":"publisher","first-page":"T159","DOI":"10.1530\/ERC-18-0015","volume":"25","author":"LV Syro","year":"2018","unstructured":"Syro LV, Rotondo F, Ortiz LD, Kovacs K (2018) 65 YEARS OF THE DOUBLE HELIX: treatment of pituitary tumors with temozolomide: an update. Endocr-Relat Cancer 25:T159\u2013T169","journal-title":"Endocr-Relat Cancer"},{"key":"441_CR26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ando.2016.02.004","volume":"77","author":"X Zheng","year":"2016","unstructured":"Zheng X, Li S, Zhang W, Zang Z, Hu J, Yang H (2016) Current biomarkers of invasive sporadic pituitary adenomas. Ann Endocrinol 77:658\u2013667","journal-title":"Ann Endocrinol"},{"key":"441_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/neurosurgery\/16.CN_suppl_1.185","volume":"16","author":"J Hardy","year":"1969","unstructured":"Hardy J (1969) Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg 16:185\u2013217","journal-title":"Clin Neurosurg"},{"key":"441_CR28","first-page":"335","volume-title":"Clinical management of pituitary disorders","author":"CB Wilson","year":"1979","unstructured":"Wilson CB (1979) Neurosurgical management of large and invasive pituitary tumors. In: Tindall GT, Collins W (eds) Clinical management of pituitary disorders. Raven Press, New York, pp 335\u2013342"},{"key":"441_CR29","first-page":"610","volume":"33","author":"E Knosp","year":"1993","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space. Neurosurgery 33:610\u2013618","journal-title":"Neurosurgery"},{"key":"441_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","volume":"122","author":"ASG Micko","year":"2015","unstructured":"Micko ASG, W\u00f6hrer A, Wolfsberger S, Knosp E (2015) Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 122:803\u2013811","journal-title":"J Neurosurg"},{"key":"441_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","volume":"126","author":"J Trouillas","year":"2013","unstructured":"Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case\u2013control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123\u2013135","journal-title":"Acta Neuropathol"},{"key":"441_CR32","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1530\/EJE-18-0250","volume":"178","author":"J Trouillas","year":"2018","unstructured":"Trouillas J, Burman P, McCormack A, Petersenn S, Popovic V, Dekkers O, Raverot G (2018) Aggressive pituitary tumours and carcinomas: two sides of the same coin? Eur J Endocrinol 178:C7\u2013C9","journal-title":"Eur J Endocrinol"},{"key":"441_CR33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1530\/EJE-17-0965","volume":"178","author":"J Lelotte","year":"2018","unstructured":"Lelotte J, Mourin A, Fomekong E, Michotte A, Raftopoulos C, Maiter (2018) Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients. Eur J Endocrinol 178:237\u2013246","journal-title":"Eur J Endocrinol"},{"key":"441_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1055\/a-1060-1883","volume":"51","author":"S Petersenn","year":"2019","unstructured":"Petersenn S (2019) Management of aggressive pituitary tumors\u2014a 2019 update. Horm Metab Res 51:755\u2013764","journal-title":"Horm Metab Res"},{"key":"441_CR35","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM, European Society of Endocrinology (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1\u2013G24","journal-title":"Eur J Endocrinol"},{"key":"441_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","volume":"17","author":"G Ravenot","year":"2021","unstructured":"Ravenot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T (2021) Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol 17:671\u2013684","journal-title":"Nat Rev Endocrinol"},{"key":"441_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40478-015-0229-8","volume":"3","author":"CP Miermeister","year":"2015","unstructured":"Miermeister CP, Petersenn S, Buchfelder M, Fahlbusch R, L\u00fcdecke DK, H\u00f6lsken A, Bergmann M, Knappe HU, Hans VH, Flitsch J et al (2015) Histological criteria for atypical pituitary adenomas\u2014data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol Commun 3:50","journal-title":"Acta Neuropathol Commun"},{"key":"441_CR38","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1210\/jc.2017-00773","volume":"102","author":"G Raverot","year":"2017","unstructured":"Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, Jouanneau E, Roy P, Trouillas J (2017) Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab 102:3368\u20133374","journal-title":"J Clin Endocrinol Metab"},{"key":"441_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1530\/EJE-18-0749","volume":"180","author":"S Asioli","year":"2019","unstructured":"Asioli S, Righi A, Iommi M, Baldovini C, Ambrosi F, Guaraldi F, Zoli M, Mazzatenta D, Faustini-Fustini M, Rucci P et al (2019) Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. Eur J Endocrinol 180:127\u2013134","journal-title":"Eur J Endocrinol"},{"key":"441_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11102-018-0863-9","volume":"21","author":"M Tampourlou","year":"2018","unstructured":"Tampourlou M, Fountas A, Ntali G, Karavitaki N (2018) Mortality in patients with non-functioning pituitary adenoma. Pituitary 21:203\u2013207","journal-title":"Pituitary"},{"key":"441_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12020-015-0685-8","volume":"50","author":"Y Greenman","year":"2015","unstructured":"Greenman Y, Stern N (2015) Optimal management of non-functioning pituitary adenomas. Endocrine 50:51\u201355","journal-title":"Endocrine"},{"key":"441_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1530\/ERC-16-0518","volume":"24","author":"DS Olsson","year":"2017","unstructured":"Olsson DS, Hammarstrand C, Bryngelsson I-L, Nilsson AG, Andersson E, Johannsson G, Ragnarsson O (2017) Incidence of malignant tumours in patients with a non-functioning pituitary adenoma. Endocr-Relat Cancer 24:227\u2013235","journal-title":"Endocr-Relat Cancer"},{"key":"441_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","volume":"134","author":"MBS Lopes","year":"2017","unstructured":"Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134:521\u2013535","journal-title":"Acta Neuropathol"},{"key":"441_CR44","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","volume":"28","author":"O Mete","year":"2017","unstructured":"Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28:228\u2013243","journal-title":"Endocr Pathol"},{"key":"441_CR45","first-page":"267","volume":"17","author":"S Chiloiro","year":"2014","unstructured":"Chiloiro S, Bianchi A, Doglietto F, de Waure C, Giampietro A, Fusco A, Iacovazzo D, Tartaglione L, Di Nardo F, Signorelli F et al (2014) Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary 17:267\u2013276","journal-title":"Pituitary"},{"key":"441_CR46","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s11102-011-0367-3","volume":"15","author":"E Hightower","year":"2012","unstructured":"Hightower E, Cabanillas ME, Fuller GN, McCutcheon IE, Hess KR, Shah K, Waguespack SG, Corley LJ, Devin JK (2012) Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Pituitary 15:556\u2013561","journal-title":"Pituitary"},{"key":"441_CR47","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1210\/jc.2009-0471","volume":"94","author":"T-W Noh","year":"2009","unstructured":"Noh T-W, Jeong HJ, Lee M-K, Kim TS, Kim SH, Lee EJ (2009) Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 94:4406\u20134413","journal-title":"J Clin Endocrinol Metab"},{"key":"441_CR48","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1210\/jc.2011-3163","volume":"97","author":"C Ram\u00edrez","year":"2012","unstructured":"Ram\u00edrez C, Cheng S, Vargas G, Asa SL, Ezzat S, Gonz\u00e1lez B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97:1745\u20131751","journal-title":"J Clin Endocrinol Metab"},{"key":"441_CR49","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.humpath.2011.12.003","volume":"43","author":"A Righi","year":"2012","unstructured":"Righi A, Agati P, Sisto A, Frank G, Faustini-Fustini M, Agati R, Mazzatenta D, Farnedi A, Menetti F, Marucci G et al (2012) A classification tree approach for pituitary adenomas. Human Pathol 43:1627\u20131637","journal-title":"Human Pathol"},{"key":"441_CR50","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1227\/00006123-199604000-00027","volume":"38","author":"K Thapar","year":"1996","unstructured":"Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765\u2013771","journal-title":"Neurosurgery"},{"key":"441_CR51","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1046\/j.1365-2265.2001.01195.x","volume":"54","author":"M Suliman","year":"2001","unstructured":"Suliman M, Royds J, Cullen D, Timperley W, Powell T, Battersby R, Jones TH (2001) Mdm2 and the p53 pathway in human pituitary adenomas. Clin Endocrinol 54:317\u2013325","journal-title":"Clin Endocrinol"},{"key":"441_CR52","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jocn.2016.09.014","volume":"34","author":"HA Zaidi","year":"2016","unstructured":"Zaidi HA, Cote DJ, Dunn IF, Laws ER Jr (2016) Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas. J Clin Neurosci 34:246\u2013251","journal-title":"J Clin Neurosci"},{"key":"441_CR53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11102-017-0855-1","volume":"21","author":"E Manojlovic-Gacic","year":"2018","unstructured":"Manojlovic-Gacic E, Engstr\u00f6m BE, Casar-Borota O (2018) Histopathological classification of non-functioning pituitary neuroendocrine tumors. Pituitary 21:119\u2013129","journal-title":"Pituitary"},{"key":"441_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10014-017-0307-7","volume":"35","author":"H Nishioka","year":"2018","unstructured":"Nishioka H, Inoshita N (2018) New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors. Brain Tumor Pathol 35:1\u20135","journal-title":"Brain Tumor Pathol"},{"key":"441_CR55","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12022-015-9398-z","volume":"26","author":"H Nishioka","year":"2015","unstructured":"Nishioka H, Inoshita N, Mete O et al (2015) The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 26:349\u2013355","journal-title":"Endocr Pathol"},{"key":"441_CR56","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11060-014-1425-2","volume":"117","author":"SE Mayson","year":"2014","unstructured":"Mayson SE, Snyder PJ (2014) Silent (clinically nonfunctioning) pituitary adenomas. J Neuro-Oncol 117:429\u2013436","journal-title":"J Neuro-Oncol"},{"key":"441_CR57","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00418-008-0472-1","volume":"130","author":"RY Osamura","year":"2008","unstructured":"Osamura RY, Kajiya H, Takei M, Egashira N, Tobita M, Takekoshi S, Teramoto A (2008) Pathology of the human pituitary adenomas. Histochem Cell Biol 130:495\u2013507","journal-title":"Histochem Cell Biol"},{"key":"441_CR58","volume-title":"Pathology and genetics of tumours of endocrine organs: World Health Organization classification of tumours","author":"RA DeLellis","year":"2004","unstructured":"DeLellis RA, Lloyd RV, Heitz PU et al (2004) Pathology and genetics of tumours of endocrine organs: World Health Organization classification of tumours. IARC Press, Lyon"},{"key":"441_CR59","first-page":"798","volume":"19","author":"SL Asa","year":"1998","unstructured":"Asa SL, Ezzat S (1998) The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19:798\u2013827","journal-title":"Endocr Rev"},{"key":"441_CR60","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-16-0738","volume":"176","author":"L Chinezu","year":"2017","unstructured":"Chinezu L, Vasiljevic A, Trouillas J, Lapoirie M, Jouanneau E, Raverot G (2017) Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. Eur J Endocrinol 176:195\u2013201","journal-title":"Eur J Endocrinol"},{"key":"441_CR61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1530\/EJE-11-0216","volume":"165","author":"AN Wade","year":"2011","unstructured":"Wade AN, Baccon J, Grady MS, Judy KD, O\u2019Rourke DM, Snyder PJ (2011) Clinically silent somatotroph adenomas are common. Eur J Endocrinol 165:39\u201344","journal-title":"Eur J Endocrinol"},{"key":"441_CR62","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","volume":"76","author":"SL Fougner","year":"2012","unstructured":"Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol 76:96\u2013102","journal-title":"Clin Endocrinol"},{"key":"441_CR63","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11102-017-0858-y","volume":"21","author":"F Langlois","year":"2018","unstructured":"Langlois F, Woltjer R, Cetas JS, Fleseriu M (2018) Silent somatotroph pituitary adenomas: an update. Pituitary 21:194\u2013202","journal-title":"Pituitary"},{"key":"441_CR64","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s12020-017-1447-6","volume":"58","author":"F Langlois","year":"2017","unstructured":"Langlois F, Lim DST, Varlamov E, Yedinak CG, Cetas JS, McCartney S, Dogan A, Fleseriu M (2017) Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience. Endocrine 58:528\u2013534","journal-title":"Endocrine"},{"key":"441_CR65","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.beem.2012.01.002","volume":"26","author":"O Cooper","year":"2012","unstructured":"Cooper O, Melmed S (2012) Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab 26:447\u2013460","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"Suppl","key":"441_CR66","first-page":"4","volume":"31","author":"K Gomez-Hernandez","year":"2015","unstructured":"Gomez-Hernandez K, Ezzat S, Asa SL, Mete O (2015) Clinical implications of accurate subtyping of pituitary adenomas: perspectives from the treating physician. Turk Patoloji Derg 31(Suppl):4\u201317","journal-title":"Turk Patoloji Derg"},{"key":"441_CR67","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11102-018-0864-8","volume":"21","author":"A Ben-Shlomo","year":"2018","unstructured":"Ben-Shlomo A, Cooper O (2018) Silent corticotroph adenomas. Pituitary 21:183\u2013193","journal-title":"Pituitary"},{"key":"441_CR68","first-page":"617","volume":"98","author":"E Horvath","year":"1980","unstructured":"Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W (1980) Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 98:617\u2013638","journal-title":"Am J Pathol"},{"key":"441_CR69","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1530\/EJE-10-0076","volume":"163","author":"G Raverot","year":"2010","unstructured":"Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, Pugeat M, Trouillas J (2010) Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing\u2019s disease. Eur J Endocrinol 163:35\u201343","journal-title":"Eur J Endocrinol"},{"key":"441_CR70","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12020-016-1028-0","volume":"56","author":"A Righi","year":"2017","unstructured":"Righi A, Faustini-Fustini M, Morandi L, Monti V, Asioli S, Mazzatenta D, Bacci A, Foschini MP (2017) The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1\/3. Endocrine 56:286\u2013297","journal-title":"Endocrine"},{"key":"441_CR71","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1227\/01.NEU.0000088660.16904.F7","volume":"53","author":"KM Webb","year":"2003","unstructured":"Webb KM, Laurent JJ, Okonkwo DO, Lopes MB, Vance ML, Laws ER Jr (2003) Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery 53:1076\u20131085","journal-title":"Neurosurgery"},{"key":"441_CR72","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1227\/01.neu.0000429858.96652.1e","volume":"73","author":"A Jahangiri","year":"2013","unstructured":"Jahangiri A, Wagner JR, Pekmezci M, Hiniker A, Chang EF, Kunwar S, Blevins L, Aghi MK (2013) A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73:8\u201317","journal-title":"Neurosurgery"},{"key":"441_CR73","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11102-014-0624-3","volume":"18","author":"O Cooper","year":"2015","unstructured":"Cooper O (2015) Silent corticotroph adenomas. Pituitary 18:225\u2013231","journal-title":"Pituitary"},{"key":"441_CR74","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1227\/01.NEU.0000290906.53685.79","volume":"61","author":"S Yamada","year":"2007","unstructured":"Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T (2007) A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61:580\u2013585","journal-title":"Neurosurgery"},{"key":"441_CR75","first-page":"1039","volume":"104","author":"A Fountas","year":"2018","unstructured":"Fountas A, Lavrentaki A, Anuradhaa Subramanian A, Toulis KA, Nirantharakumar K, Karavitaki N (2018) Recurrence of silent corticotroph adenomas after primary treatment: a systematic review and meta-analysis. J Clin Endocrinol Metab 104:1039\u20131048","journal-title":"J Clin Endocrinol Metab"},{"key":"441_CR76","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11102-017-0809-7","volume":"20","author":"AF Cheres","year":"2017","unstructured":"Cheres AF, ElAsmar N, Rajpal A, Selman WR, Arafah BM (2017) Perioperative hypothalamic pituitary adrenal function in patients with silent corticotroph adenomas. Pituitary 20:471\u2013476","journal-title":"Pituitary"},{"key":"441_CR77","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1750-3639.2012.00599.x","volume":"22","author":"O Mete","year":"2012","unstructured":"Mete O, Asa SL (2012) Clinicopathological correlations in pituitary adenomas. Brain Pathol 22:443\u2013453","journal-title":"Brain Pathol"},{"key":"441_CR78","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12022-018-9521-z","volume":"29","author":"SL Asa","year":"2018","unstructured":"Asa SL, Mete O (2018) Immunohistochemical biomarkers in pituitary pathology. Endocr Pathol 29:130\u2013136","journal-title":"Endocr Pathol"},{"key":"441_CR79","first-page":"227","volume":"6","author":"E Thodou","year":"2007","unstructured":"Thodou E, Argyrakos T, Kontogeorgos G (2007) Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones (Athens) 6:227\u2013232","journal-title":"Hormones (Athens)"},{"key":"441_CR80","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12022-013-9270-y","volume":"24","author":"O Mete","year":"2013","unstructured":"Mete O, Hayhurst C, Alahmadi H, Monsalves E, Gucer H, Gentili F, Ezzat S, Asa SL, Zadeh G (2013) The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas. Endocr Pathol 24:191\u2013198","journal-title":"Endocr Pathol"},{"key":"441_CR81","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/02688690500081230","volume":"19","author":"SE Baldeweg","year":"2005","unstructured":"Baldeweg SE, Pollock JR, Powell M, Ahlquist J (2005) A spectrum of behaviour in silent corticotroph pituitary adenomas. Br J Neurosurg 19:38\u201342","journal-title":"Br J Neurosurg"},{"key":"441_CR82","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.3171\/2014.11.FOCUS14679","volume":"38","author":"M Zoli","year":"2015","unstructured":"Zoli M, Faustini-Fustini M, Mazzatenta D, Marucci G, De Carlo E, Bacci A, Pasquini E, Lanzino G, Frank G (2015) ACTH adenomas transforming their clinical expression: report of 5 cases. Neurosurg Focus 38:E15","journal-title":"Neurosurg Focus"},{"key":"441_CR83","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1530\/EJE-07-0428","volume":"157","author":"T Tateno","year":"2007","unstructured":"Tateno T, Izumiyama H, Doi M, Yoshimoto T, Shichiri M, Inoshita N, Oyama K, Yamada S, Hirata Y (2007) Differential gene expression in ACTH -secreting and non-functioning pituitary tumors. Eur J Endocrinol 157:717\u2013724","journal-title":"Eur J Endocrinol"},{"key":"441_CR84","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11060-017-2520-y","volume":"135","author":"O Cohen-Inbar","year":"2017","unstructured":"Cohen-Inbar O, Xu Z, Lee C-C, Wu CC, Chytka T, Silva D, Sharma M, Radwan H, Grills IS, Nguyen B et al (2017) Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study. J Neuro-Oncol 135:67\u201374","journal-title":"J Neuro-Oncol"},{"key":"441_CR85","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12672-010-0014-x","volume":"1","author":"O Cooper","year":"2010","unstructured":"Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S (2010) Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer 1:80\u201392","journal-title":"Horm Cancer"},{"key":"441_CR86","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.wneu.2014.03.031","volume":"82","author":"MA Kirkman","year":"2014","unstructured":"Kirkman MA, Jaunmuktane Z, Brandner S, Khan AA, Powell M, Baldeweg SE (2014) Active and silent thyroid-stimulating hormone\u2212expressing pituitary adenomas: presenting symptoms, treatment, outcomes, and recurrence. World Neurosurg 82:1224\u20131231","journal-title":"World Neurosurg"},{"key":"441_CR87","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/eje.1.02326","volume":"156","author":"DK L\u00fcdecke","year":"2007","unstructured":"L\u00fcdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156:203\u2013216","journal-title":"Eur J Endocrinol"},{"key":"441_CR88","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000192449","volume":"71","author":"M Korbonits","year":"2009","unstructured":"Korbonits M, Carlsen E (2009) Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm Res Paediatr 71:123\u2013130","journal-title":"Horm Res Paediatr"},{"key":"441_CR89","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12022-014-9347-2","volume":"26","author":"JA Balogun","year":"2015","unstructured":"Balogun JA, Monsalves E, Juraschka K, Parvez K, Kucharczyk W, Mete O, Gentili F, Zadeh G et al (2015) Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics. Endocr Pathol 26:63\u201370","journal-title":"Endocr Pathol"},{"key":"441_CR90","doi-asserted-by":"publisher","first-page":"356","DOI":"10.5858\/arpa.2014-0020-OA","volume":"139","author":"BK Kleinschmidt-DeMasters","year":"2015","unstructured":"Kleinschmidt-DeMasters BK, Lopes MBS, Prayson RA (2015) An algorithmic approach to sellar region masses. Arch Pathol Lab Med 139:356\u2013372","journal-title":"Arch Pathol Lab Med"},{"key":"441_CR91","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1365-2265.2008.03514.x","volume":"71","author":"D Erickson","year":"2009","unstructured":"Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF Jr (2009) Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol 71:92\u201399","journal-title":"Clin Endocrinol"},{"key":"441_CR92","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1210\/jc.2004-2231","volume":"90","author":"GA Kaltsas","year":"2005","unstructured":"Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90:3089\u20133099","journal-title":"J Clin Endocrinol Metab"},{"key":"441_CR93","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/cancers12020308","volume":"12","author":"LS Lamb","year":"2020","unstructured":"Lamb LS, Sim H-W, Ann I, McCormack AI (2020) Exploring the role of novel medical therapies for aggressive pituitary tumors: a review of the literature \u201care we there yet?\u201d Cancers 12:308. https:\/\/doi.org\/10.3390\/cancers12020308","journal-title":"Cancers"},{"key":"441_CR94","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1677\/ERC-08-0167","volume":"16","author":"Y Lin","year":"2009","unstructured":"Lin Y, Jiang X, Shen Y, Li M, Ma H, Xing M, Lu Y (2009) Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr-Relat Cancer 16:301\u2013310","journal-title":"Endocr-Relat Cancer"},{"key":"441_CR95","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12022-009-9076-0","volume":"20","author":"MG Hossain","year":"2009","unstructured":"Hossain MG, Iwata T, Mizusawa N, Qian ZR, Shima SW, Okutsu T, Yamada S, Sano T, Yoshimoto K (2009) Expression of p18INK4C is down-regulated in human pituitary adenomas. Endocr Pathol 20:114\u2013121","journal-title":"Endocr Pathol"},{"key":"441_CR96","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/onc.2011.245","volume":"31","author":"G Bulut","year":"2012","unstructured":"Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshanamurthy S, Lee H-S, Daar I, Toretsky JA et al (2012) Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 31:269\u2013281","journal-title":"Oncogene"},{"key":"441_CR97","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.wneu.2017.01.010","volume":"100","author":"Y Chen","year":"2017","unstructured":"Chen Y, Chuan H-L, Yu S-Y, Li CZ, Wu ZB, Li GL, Zhang YZ (2017) A novel invasive-related biomarker in three subtypes of nonfunctioning pituitary adenomas. World Neurosurg 100:514\u2013521","journal-title":"World Neurosurg"},{"key":"441_CR98","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.mce.2018.01.020","volume":"473","author":"P Kober","year":"2018","unstructured":"Kober P, Boresowicz J, Rusetska N, Maksymowicz M, Goryca K, Kunicki J, Bonicki W, Siedlecki JA, Bujko M (2018) DNA methylation profiling in nonfunctioning pituitary adenomas. Mol Cell Endocrinol 473:194\u2013204","journal-title":"Mol Cell Endocrinol"},{"key":"441_CR99","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/(SICI)1098-2264(199904)24:4<328::AID-GCC6>3.0.CO;2-P","volume":"24","author":"DJ Simpson","year":"1999","unstructured":"Simpson DJ, Bicknell JE, McNicol AM, Clayton RN, Farrell WE (1999) Hypermethylation of thep16\/CDKN2A\/MTS1 gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes Chromosomes Cancer 24:328\u2013336","journal-title":"Genes Chromosomes Cancer"},{"key":"441_CR100","first-page":"1262","volume":"87","author":"X Zhang","year":"2002","unstructured":"Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B, Klibanski A (2002) Loss of expression of GADD45\u03b3, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 87:1262\u20131267","journal-title":"J Clin Endocrinol Metab"},{"key":"441_CR101","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1210\/jc.2003-030222","volume":"88","author":"X Zhang","year":"2003","unstructured":"Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A (2003) A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 88:5119\u20135126","journal-title":"J Clin Endocrinol Metab"},{"key":"441_CR102","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/435171","volume":"2014","author":"X-H Li","year":"2014","unstructured":"Li X-H, Wang EL, Zhou H-M, Yoshimoto K, Qian ZR (2014) MicroRNAs in human pituitary adenomas. Int J Endocrinol 2014:435171","journal-title":"Int J Endocrinol"},{"key":"441_CR103","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215\u2013233","journal-title":"Cell"},{"key":"441_CR104","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10528-017-9794-9","volume":"55","author":"S Wu","year":"2017","unstructured":"Wu S, Gu Y, Huang Y, Wong TC, Ding H, Liu T, Zhang Y, Zhang X (2017) Novel biomarkers for non-functioning invasive pituitary adenomas were identified by using analysis of microRNAs expression profile. Biochem Genet 55:253\u2013267","journal-title":"Biochem Genet"},{"key":"441_CR105","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1055\/s-0043-106437","volume":"49","author":"W Zhen","year":"2017","unstructured":"Zhen W, Qiu D, Zhiyong C, Xin W, Mengyao J, Dimin Z, Chonghui H, Haijun W, Yonghong Z (2017) MicroRNA-524-5p functions as a tumor suppressor in a human uitary tumor-derived cell line. Horm Metab Res 49:550\u2013557","journal-title":"Horm Metab Res"},{"key":"441_CR106","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1210\/jc.2010-0581","volume":"95","author":"H Butz","year":"2010","unstructured":"Butz H, Lik\u00f3 I, Czirj\u00e1k S, Igaz P, Khan MM, Zivkovic V, B\u00e1lint K, Korbonits M, R\u00e1cz K, Pat\u00f3cs A (2010) Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. J Clin Endocrinol Metab 95:181\u2013191","journal-title":"J Clin Endocrinol Metab"},{"key":"441_CR107","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.mce.2018.03.005","volume":"474","author":"W Song","year":"2018","unstructured":"Song W, Qian L, Jing G, Jie F, Xiaosong S, Chunhui L, Yangfang L, Guilin L, Gao H, Yazhuo Z (2018) Aberrant expression of the sFRP and WIF1 genes in invasive non-functioning pituitary adenomas. Mol Cell Endocrinol 474:168\u2013175","journal-title":"Mol Cell Endocrinol"},{"key":"441_CR108","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.ajpath.2011.07.002","volume":"179","author":"P Cheunsuchon","year":"2011","unstructured":"Cheunsuchon P, Zhou Y, Zhang X, Lee H, Chen W, Nakayama Y, Rice KA, Tessa Hedley-Whyte E, Swearingen B, Klibanski A (2011) Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas. Am J Pathol 179:2120\u20132130","journal-title":"Am J Pathol"},{"key":"441_CR109","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.mce.2016.07.025","volume":"436","author":"J Feng","year":"2016","unstructured":"Feng J, Yu S-Y, Li C-Z, Li ZY, Zhang YZ (2016) Integrative proteomics and transcriptomics revealed that activation of the IL-6R\/JAK2\/STAT3\/MMP9 signaling pathway is correlated with invasion of pituitary null cell adenomas. Mol Cell Endocrinol 436:195\u2013203","journal-title":"Mol Cell Endocrinol"},{"key":"441_CR110","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003904","volume":"95","author":"H-Y Liu","year":"2016","unstructured":"Liu H-Y, Gu W-J, Wang C-Z, Ji XJ, Mu YM (2016) Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: a systematic review and meta-analysis of case-control trials. Medicine 95:e3904","journal-title":"Medicine"},{"key":"441_CR111","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nrc2271","volume":"7","author":"A Fusco","year":"2007","unstructured":"Fusco A, Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7:899\u2013910 ((Yao et al., 2017)[148])","journal-title":"Nat Rev Cancer"},{"key":"441_CR112","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11060-016-2365-9","volume":"132","author":"X Yao","year":"2017","unstructured":"Yao X, Gao H, Li C, Wu L, Bai J, Wang J, Li Y, Zhang Y (2017) Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas. J Neuro-Oncol 132:199\u2013206","journal-title":"J Neuro-Oncol"},{"key":"441_CR113","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/01902140490495499","volume":"31","author":"R Lubet","year":"2005","unstructured":"Lubet R, Wang Y, Zhang Z, You M (2005) Mouse models incorporating alterations in the major tumor suppressor genes P53 and P16: their use in screening for potential carcinogens, developing further relevant mouse models, and screening for potential chemopreventive and chemotherapeutic agents. Exp Lung Res 31:117\u2013133","journal-title":"Exp Lung Res"},{"key":"441_CR114","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.mce.2019.04.010","volume":"490","author":"S Portovedo","year":"2019","unstructured":"Portovedo S, Gaido N, de Almeida NB, Nascimento AG, Rocha A, Magalh\u00e3es M, Nascimento GC, Pires de Carvalho D, Soares P, Takiya C et al (2019) Differential expression of HMGA1 and HMGA2 in pituitary neuroendocrine tumors. Mol Cell Endocrinol 490:80\u201387","journal-title":"Mol Cell Endocrinol"},{"key":"441_CR115","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/00313020701329914","volume":"39","author":"M Guarino","year":"2007","unstructured":"Guarino M, Rubino B, Ballabio G (2007) The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39:305\u2013318","journal-title":"Pathology"},{"key":"441_CR116","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ceb.2016.06.002","volume":"43","author":"M Diepenbruck","year":"2016","unstructured":"Diepenbruck M, Christofori G (2016) Epithelial\u2013mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr Opin Cell Biol 43:7\u201313","journal-title":"Curr Opin Cell Biol"},{"key":"441_CR117","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1210\/jc.2008-2075","volume":"94","author":"MS Elston","year":"2009","unstructured":"Elston MS, Gill AJ, Conaglen JV, Cook RJ, Little NS, Robinson BG, Clifton-Bligh RJ, McDonald KL (2009) Nuclear accumulation of E-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J Clin Endocrinol Metab 94:1436\u20131442","journal-title":"J Clin Endocrinol Metab"},{"key":"441_CR118","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1210\/jc.2010-3040","volume":"96","author":"W Zhou","year":"2011","unstructured":"Zhou W, Song Y, Xu H, Zhou K, Zhang W, Chen J, Qin M, Yi H, Gustafsson JA, Yang H et al (2011) In nonfunctional pituitary adenomas, estrogen receptors and slug contribute to development of invasiveness. J Clin Endocrinol Metab 96:1237\u20131245","journal-title":"J Clin Endocrinol Metab"},{"key":"441_CR119","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12020-018-1679-0","volume":"62","author":"KAB \u00d8ystese","year":"2018","unstructured":"\u00d8ystese KAB, Berg JP, Normann KR, Zucknick M, Casar-Borota O, Bollerslev J (2018) The role of E and N-cadherin in the postoperative course of gonadotroph pituitary tumours. Endocrine 62:351\u2013360","journal-title":"Endocrine"},{"key":"441_CR120","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1677\/joe.0.1510175","volume":"151","author":"ML Jaffrain-Rea","year":"1996","unstructured":"Jaffrain-Rea ML, Petrangeli E, Ortolani F, Fraioli B, Lise A, Esposito V, Spagnoli LG, Tamburrano G, Frati L, Gulino A (1996) Cellular receptors for sex steroids in human pituitary adenomas. J Endocrinol 151:175\u2013184","journal-title":"J Endocrinol"},{"key":"441_CR121","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1210\/jc.2017-00792","volume":"102","author":"KA Oystese","year":"2017","unstructured":"Oystese KA, Casar-Borota O, Normann KR, Zucknick M, Berg JP, Bollerslev J (2017) Estrogen receptor \u03b1, a sex-dependent predictor of aggressiveness in nonfunctioning pituitary adenomas: SSTR and sex hormone receptor distribution in NFPA. J Clin Endocrinol Metab 102:3581\u20133590","journal-title":"J Clin Endocrinol Metab"},{"key":"441_CR122","unstructured":"Falch CM (2017) Gene expression profiling of growing gonadotroph non-functioning pituitary adenomas Objectived. Eur J Endocrinol 1\u201332"},{"key":"441_CR123","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massagu\u00e9","year":"2012","unstructured":"Massagu\u00e9 J (2012) TGF\u03b2 signalling in context. Nat Rev Mol Cell Biol 13:616\u2013630 (Zavaldi and B\u00f6ttinger, 2005) [87, 151])","journal-title":"Nat Rev Mol Cell Biol"},{"key":"441_CR124","doi-asserted-by":"publisher","first-page":"5764","DOI":"10.1038\/sj.onc.1208927","volume":"24","author":"J Zavadil","year":"2005","unstructured":"Zavadil J, B\u00f6ttinger EP (2005) TGF-\u03b2 and epithelial-to-mesenchymal transitions. Oncogene 24:5764\u20135774","journal-title":"Oncogene"},{"key":"441_CR125","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jocn.2017.07.033","volume":"47","author":"Y-H Gu","year":"2018","unstructured":"Gu Y-H, Feng Y-G (2018) Down-regulation of TGF-\u03b2 RII expression is correlated with tumor growth and invasion in non-functioning pituitary adenomas. J Clin Neurosci 47:264\u2013268","journal-title":"J Clin Neurosci"},{"key":"441_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-12-71","volume":"12","author":"L Zhenye","year":"2014","unstructured":"Zhenye L, Chuzhong L, Youtu W, Xiaolei L, Lei C, Lichuan H, Hongyun W, Yonggang W, Fei W, Yazhuo Z (2014) The expression of TGF-\u03b21, Smad3, phospho-Smad3 and Smad7 is correlated with the development and invasion of nonfunctioning pituitary adenomas. J Transl Med 12:1\u20138","journal-title":"J Transl Med"},{"key":"441_CR127","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.2147\/OTT.S99699","volume":"9","author":"C Liu","year":"2016","unstructured":"Liu C, Li Z, Wu D, Li C, Zhang Y (2016) Smad3 and phospho-Smad3 are potential markers of invasive nonfunctioning pituitary adenomas. OncoTargets Ther 9:2265\u20132271","journal-title":"OncoTargets Ther"},{"key":"441_CR128","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s11102-010-0268-x","volume":"14","author":"H Butz","year":"2011","unstructured":"Butz H, Lik\u00f3 I, Czirj\u00e1k S, Igaz P, Korbonits M, R\u00e1cz K, Pat\u00f3cs A (2011) MicroRNA profile indicates downregulation of the TGF\u03b2 pathway in sporadic non-functioning pituitary adenomas. Pituitary 14:112\u2013124","journal-title":"Pituitary"},{"key":"441_CR129","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","volume":"149","author":"H Clevers","year":"2012","unstructured":"Clevers H, Nusse R (2012) Wnt\/\u03b2-catenin signaling and disease. Cell 149:1192\u20131205","journal-title":"Cell"},{"key":"441_CR130","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.molmed.2012.06.008","volume":"18","author":"P Herr","year":"2012","unstructured":"Herr P, Hausmann G, Basler K (2012) WNT secretion and signalling in human disease. Trends Mol Med 18:483\u2013493","journal-title":"Trends Mol Med"},{"key":"441_CR131","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.gde.2006.12.007","volume":"17","author":"P Polakis","year":"2007","unstructured":"Polakis P (2007) The many ways of Wnt in cancer. Curr Opin Genet Dev 17:45\u201351","journal-title":"Curr Opin Genet Dev"},{"key":"441_CR132","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3892\/mmr.2017.6169","volume":"15","author":"C Liu","year":"2017","unstructured":"Liu C, Wu Y, Yu S, Bai J, Li C, Wu D, Zhang Y (2017) Increased \u03b2-catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: an assessment using a tissue microarray-based approach. Mol Med Rep 15:1793\u20131799","journal-title":"Mol Med Rep"},{"key":"441_CR133","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015081","volume":"5","author":"C-M Cruciat","year":"2013","unstructured":"Cruciat C-M, Niehrs C (2013) Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol 5:a015081","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"441_CR134","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ygyno.2008.10.026","volume":"112","author":"M-T Chung","year":"2009","unstructured":"Chung M-T, Lai H-C, Sytwu H-K, Yan MD, Shih YL, Chang CC, Yu MH, Liu HS, Chu DW, Lin YW (2009) SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol Oncol 112:646\u2013653","journal-title":"Gynecol Oncol"},{"key":"441_CR135","doi-asserted-by":"publisher","first-page":"7081","DOI":"10.1158\/0008-5472.CAN-05-0267","volume":"65","author":"CJ Marsit","year":"2005","unstructured":"Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR, Nelson HH, Kelsey KT (2005) Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res 65:7081\u20137085","journal-title":"Cancer Res"},{"key":"441_CR136","first-page":"842","volume":"29","author":"J Qi","year":"2007","unstructured":"Qi J, Zhu Y-Q, Luo J, Tao WH, Zhang JM (2007) Hypermethylation and regulation of expression of secreted frizzled-related protein genes in colorectal tumor. Zhonghua Zhong Liu Za Zhi [Chinese J Oncol] 29:842\u2013845","journal-title":"Zhonghua Zhong Liu Za Zhi [Chinese J Oncol]"},{"key":"441_CR137","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3892\/ol.2016.4560","volume":"12","author":"Y Wu","year":"2016","unstructured":"Wu Y, Bai J, Hong L, Liu C, Yu S, Yu G, Zhang Y (2016) Low expression of secreted frizzled-related protein 2 and nuclear accumulation of \u03b2-catenin in aggressive nonfunctioning pituitary adenoma. Oncol Lett 12:199\u2013206","journal-title":"Oncol Lett"},{"key":"441_CR138","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0898-6568(01)00271-6","volume":"14","author":"KM Nicholson","year":"2002","unstructured":"Nicholson KM, Anderson NG (2002) The protein kinase B\/Akt signalling pathway in human malignancy. Cell Signal 14:381\u2013395","journal-title":"Cell Signal"},{"key":"441_CR139","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase\u2013AKT pathway in human cancer. Nat Rev Cancer 2:489\u2013501","journal-title":"Nat Rev Cancer"},{"key":"441_CR140","doi-asserted-by":"publisher","first-page":"E1411","DOI":"10.1210\/jc.2012-1111","volume":"97","author":"HS Chahal","year":"2012","unstructured":"Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chapple JP, Jordan S, Amelie Lupp A et al (2012) Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 97:E1411\u2013E1420","journal-title":"J Clin Endocrinol Metab"},{"key":"441_CR141","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-05-1189","volume":"66","author":"M Theodoropoulou","year":"2006","unstructured":"Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U, Stalla GK (2006) Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 66:1576\u20131582","journal-title":"Cancer Res"},{"key":"441_CR142","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mce.2010.01.033","volume":"326","author":"M Theodoropoulou","year":"2010","unstructured":"Theodoropoulou M, Stalla GK, Spengler D (2010) ZAC1 target genes and pituitary tumorigenesis. Mol Cell Endocrinol 326:60\u201365","journal-title":"Mol Cell Endocrinol"},{"key":"441_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0077406","volume":"8","author":"L Vieria Neto","year":"2013","unstructured":"Vieria Neto L, Wildemberg LE, Colli LM, Kasuki L, Marques NV, Moraes AB, Gasparetto EL, Takiya CM, Castro M, Gadelha MR (2013) ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas. PLoS ONE 8:1\u20137","journal-title":"PLoS ONE"},{"key":"441_CR144","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mce.2016.10.005","volume":"445","author":"G Carreno","year":"2017","unstructured":"Carreno G, Gonzalez-Meljem JM, Haston S, Martinez-Barbera JP (2017) Stem cells and their role in pituitary tumorigenesis. Mol Cell Endocrinol 445:27\u201334","journal-title":"Mol Cell Endocrinol"},{"key":"441_CR145","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s40478-016-0394-4","volume":"4","author":"B Manoranjan","year":"2016","unstructured":"Manoranjan B, Mahendram S, Almenawer SA, Venugopal C, McFarlane N, Hallett R, Vijayakumar T, Algird A, Murty NK, Sommer DD et al (2016) The identification of human pituitary adenoma-initiating cells. Acta Neuropathol Commun 4:125","journal-title":"Acta Neuropathol Commun"},{"key":"441_CR146","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11102-018-0874-6","volume":"21","author":"MC Zatelli","year":"2018","unstructured":"Zatelli MC (2018) Pathogenesis of non-functioning pituitary adenomas. Pituitary 21:130\u2013137","journal-title":"Pituitary"},{"key":"441_CR147","doi-asserted-by":"publisher","first-page":"4879","DOI":"10.1007\/s12035-016-0025-x","volume":"54","author":"R W\u00fcrth","year":"2017","unstructured":"W\u00fcrth R, Barbieri F, Pattarozzi A, Gaudenzi G, Gatto F, Fiaschi P, Ravetti JL, Zona G, Daga A, Persani L et al (2017) Phenotypical and pharmacological characterization of stem-like cells in human pituitary adenomas. Mol Neurobiol 54:4879\u20134895","journal-title":"Mol Neurobiol"},{"key":"441_CR148","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/ijc.30613","volume":"140","author":"E Peverelli","year":"2017","unstructured":"Peverelli E, Giardino E, Treppiedi D, Meregalli M, Belicchi M, Vaira V, Corbetta S, Verdelli C, Verrua E, Serban AL et al (2017) Dopamine receptor type 2 ( DRD2) and somatostatin receptor type 2 ( SSTR2) agonists are effective in inhibiting proliferation of progenitor\/stem-like cells isolated from nonfunctioning pituitary tumors. Int J Cancer 140:1870\u20131880","journal-title":"Int J Cancer"},{"key":"441_CR149","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480\u2013489","journal-title":"Nature"},{"key":"441_CR150","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/jnen\/nlx072","volume":"76","author":"TE Richardson","year":"2017","unstructured":"Richardson TE, Shen Z-J, Kanchwala M, Xing C, Filatenkov A, Shang P, Barnett S, Abedin Z, Malter JS, Raisanen JM et al (2017) Aggressive behavior in silent subtype III pituitary adenomas may depend on suppression of local immune response: a whole transcriptome analysis. J Neuropathol Exp Neurol 76:874\u2013882","journal-title":"J Neuropathol Exp Neurol"},{"key":"441_CR151","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-018-2844-2","volume":"139","author":"P-F Wang","year":"2018","unstructured":"Wang P-F, Wang T-J, Yang Y-K, Yao K, Li Z, Li YM, Yan CX (2018) The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy. J Neuro-Oncol 139:89\u201395","journal-title":"J Neuro-Oncol"},{"key":"441_CR152","doi-asserted-by":"publisher","first-page":"76565","DOI":"10.18632\/oncotarget.12088","volume":"7","author":"Y Mei","year":"2016","unstructured":"Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY, Kaiser UB, Woodmansee WW, Reardon DA, Freeman GJ, Fecci PE, Laws ER Jr et al (2016) Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget 7:76565\u201376576","journal-title":"Oncotarget"},{"key":"441_CR153","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1046\/j.1365-2265.2003.01784.x","volume":"58","author":"Y Greenman","year":"2003","unstructured":"Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N (2003) Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin Endocrinol 58:763\u2013769","journal-title":"Clin Endocrinol"},{"key":"441_CR154","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3171\/JNS\/2008\/108\/4\/0736","volume":"108","author":"EF Chang","year":"2008","unstructured":"Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell JB, Wilson CB, Sandeep Kunwar S (2008) Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 108:736\u2013745","journal-title":"J Neurosurg"},{"key":"441_CR155","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3171\/JNS\/2008\/108\/3\/0525","volume":"108","author":"M Losa","year":"2008","unstructured":"Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108:525\u2013532","journal-title":"J Neurosurg"},{"key":"441_CR156","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2265.2009.03583.x","volume":"71","author":"EP O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan EP, Woods C, Glynn N, Behan LA, Crowley R, O\u2019Kelly P, Smith D, Thompson CJ, Agha A (2009) The natural history of surgically treated but radiotherapy-na\u00efve nonfunctioning pituitary adenomas. Clin Endocrinol 71:709\u2013714","journal-title":"Clin Endocrinol"},{"key":"441_CR157","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/00006123-200010000-00009","volume":"47","author":"M Kurosaki","year":"2000","unstructured":"Kurosaki M, L\u00fcdecke DK, Flitsch J, Saeger W (2000) Surgical treatment of clinically nonsecreting pituitary adenomas in elderly patients. Neurosurgery 47:843\u2013849","journal-title":"Neurosurgery"},{"key":"441_CR158","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s11102-018-0865-7","volume":"21","author":"N Even-Zohar","year":"2018","unstructured":"Even-Zohar N, Greenman Y (2018) Management of NFAs: medical treatment. Pituitary 21:168\u2013175","journal-title":"Pituitary"},{"key":"441_CR159","doi-asserted-by":"publisher","first-page":"E533","DOI":"10.1227\/NEU.0000000000001389","volume":"79","author":"JW Lucas","year":"2016","unstructured":"Lucas JW, Bodach ME, Tumialan LM et al (2016) Congress of neurological surgeons systematic review and evidence-based guideline on primary management of patients with nonfunctioning pituitary adenomas. Neurosurgery 79:E533\u2013E535","journal-title":"Neurosurgery"},{"key":"441_CR160","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3171\/2013.11.JNS131757","volume":"120","author":"C-C Lee","year":"2014","unstructured":"Lee C-C, Kano H, Yang H-C, Xu Z, Yen CP, Chung WY, Pan DH, Lunsford LD, Sheehan JP (2014) Initial gamma knife radiosurgery for nonfunctioning pituitary adenomas. J Neurosurg 120:647\u2013654","journal-title":"J Neurosurg"},{"key":"441_CR161","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3390\/jcm8081107","volume":"8","author":"MD Ilie","year":"2019","unstructured":"Ilie MD, Lasolle H, Raverot G (2019) Emerging and novel treatments for pituitary tumors. J Clin Med 8:1107","journal-title":"J Clin Med"}],"container-title":["Brain Tumor Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-022-00441-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10014-022-00441-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-022-00441-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T04:29:52Z","timestamp":1664339392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10014-022-00441-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":161,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["441"],"URL":"https:\/\/doi.org\/10.1007\/s10014-022-00441-6","relation":{},"ISSN":["1433-7398","1861-387X"],"issn-type":[{"value":"1433-7398","type":"print"},{"value":"1861-387X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"1 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}